Hormone replacement therapy and risk of cardiovascular disease: Implications of the results of the Women's Health Initiative

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 1, 2003, Pages 11-16

  Kuller, Lewis H ^a  

^a NONE

Author keywords

Clinical trials; Coronary heart disease; Estrogen; Hormones; Stroke

Indexed keywords

C REACTIVE PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; PROTHROMBIN; TAMOXIFEN; THROMBIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; GENETIC VARIABILITY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SHORT SURVEY; STROKE; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTERONE; RISK FACTORS; WOMEN'S HEALTH;

EID: 0037236616     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000046033.32478.6D     Document Type: Short Survey

References (70)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2000;288:321-333.
2. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57.
3. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement therapy on the progression of coronary artery atherosclerosis. N Engl J Med. 2000;343:522-529.
4. Angerer P, Stork S, Kothny W, Schmitt P, von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:262-268.
5. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu C-R, Liu C-H, Azen SP, for the Estrogen I the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
6. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
7. Mishell DR Jr, Mendelsohn ME. Introduction: the role of hormone replacement therapy in prevention and treatment of cardiovascular disease in postmenopausal women. Am J Cardiol. 2002;89(suppl 12A):1E-4E.
8. Sullivan JM, Fowlkes LP. Estrogens, menopause, and coronary artery disease. Cardiol Clin. 1996;14:105-116.
9. Marmorston J, Moore FJ, Hopkins CE. Clinical studies of long-term estrogen therapy in men with myocardial infarction. Ann Intern Med. 1962;110:400-408.
10. The Coronary Drug Project Research Group. The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303-1313.
11. Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA. 1973;226:652-657.
12. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W, for the Coronary Drug Project Research Group. Fifteen year mortality in coronary drug project patients: long-term benefit with Niacin. J Am Coll Cardiol. 1986;8:1245-1255.
13. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 2001;21:255-261.
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
15. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M, for the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial investigators. Cardiovascular effects of Tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst. 2001;93:16-21.
16. Gianturco SH, Bradley WA. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Clin Cardiol. 1999;22(suppl II):II-7-II-14.
17. Grundy SM. Hypertriglyceridemia, atherogenic dyslipemic and the metabolic syndrome. Am J Cardiol. 1998;81:18B-25B.
18. Hodis HN, Mack WJ, Krauss RM, Alaupovic P. Pathophysiology of triglyeeride-rich lipoproteins in atherothrombosis: clinical aspects. Clin Cardiol. 1999;22(suppl II):II-15-II-20.
19. Coresh J, Kwiterovich PO Jr, Smith HH, Bachorik PS. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993;34:1687-1697.
20. Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis. 1994;110(suppl): S83-S91.
21. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
22. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
23. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2002;22:1175-1180.
24. Kamigaki AS, Siscovick DS, Schwartz SM, Psaty BM, Edwards KL, Raghunathan TE, Austin MA. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol. 2001;153:939-945.
25. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HJ, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation. 1999;110:717-722.
26. Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol. 2001;153:1094-1101.
27. Cushman M. Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation. Am J Cardiol. 2002;9(suppl):7F-10F.
28. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW. Effects of Raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445-1451.
29. Wenger NK. Cardiovascular effects of Raloxifene: the potential for cardiovascular protection in women. Diabetes Obes Metab. 2002;4:166-176.
30. Kuller LH, Matthews KA, Sutton-Tyrrell K, Edmundowicz D, Bunker CH. Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: the Healthy Women Study. Arterioscler Thromb Vasc Biol. 1999;19:2189-2198.
31. Martin P, Moyer MP, Tracy RP, Tracy PB, van't Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol. 1998;18:458-465.
32. Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol. 2000;23(suppl VI):VI-3-VI-7.
33. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year double-blind, placebo-controlled study. Thromb Haemost. 1996;75:476-480.
34. Nabulsi A, Folsom A, White A, Patsch W, Heiss G, Wu K, Szklo M. Investigators for the Atherosclerosis Risk in Communities Study: association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1069-1075.
35. Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17:3071-3078.
36. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992;68:392-395.
37. Cushman M, Psaty BM, Meilahn EN, Dobs AS, Kuller LH. Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women. Br J Haematol. 2001;114:162-168.
38. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN. Effect of Tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol. In press.
39. Gottsater A, Rendell M, Hulthen UL, Bemtorp E, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Int Med. 2001;249:237-246.
40. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76:13-24.
41. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534-1539.
42. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill RE. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vase Biol. 2000;20:1404-1409.
43. Koh KK, Horne III MK, Cannon III RO. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women. Thromb Haemost. 1999;83:626-633.
44. Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism: results from a randomized, double-blind, clinical trial. Thromb Haemost. 2001;85:775-781.
45. Douketis JD, Gordon M, Johnston M, Julian JA, Adachi JR, Ginsberg JS. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein c: prospective cohort study and review of the literature. Thromb Res. 2000;99:25-34.
46. Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, Bowden D, Bittner V, Simon JA, Grady D, Hulley SB. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002;22:1012-1017.
47. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
48. Iacoviello L, Vischetti M, Zito F, Donati MB. Genes encoding fibrinogen and cardiovascular risk. Hypertension. 2001;38:1199-1203.
49. Reiner AP, Rosendaal FR, Reitsma PH, Lemaitre RN, Pearce RM, Friedlander Y, Raghunathan TE, Psaty BM, Siscovick DS. Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol. 2002;90:66-68.
50. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA. 2001;285:906-913.
51. Mielke CH, Shields JP, Broemeling LD. Coronary artery calcium scores for men and women of a large asymptomatic population. CVD Prev. 1999;2:194-198.
52. Church TS, Blair S, Nichaman M, Cheng Y-L, Kimball T, Gibbons L, Levine B, Cooper K. Coronary artery calcium score and risk of CHD events. Abstract presented at the AHA 42nd Annual Conference on Cardiovascular Disease: Epidemiology and Prevention. April 23-26, 2002: Honolulu, Hawaii. Abstract No. P2.
53. Sutton-Tyrrell K, Kuller LH, Edmundowicz E, Feldman A, Holubkov R, Givens L, Matthews KA. Usefulness of electron beam tomography to detect progression of coronary and aortic calcium in middle-aged women. Am J Cardiol. 2001;87:560-564.
54. Colhoun HM, Otvos JD, Rubens MB, Taskinen MR, Underwood SR, Fuller JH. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type I diabetes. Diabetes. 2002;51:1949-1956.
55. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with Simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med. 1997;337:595-601.
56. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J, for the Scandinavian Simvastatin Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: finding from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-4218.
57. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
58. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald E, for the CARE investigators. Effect of Pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol. 1998;32:140-146.
59. The Lipid Research Clinics Program. The lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
60. Ekelund L-G, Suchindran CM, McMahon RP, Heiss G, Leon AS, Romhilt DW, Rubenstein CL, Probstfield JL, Ruwitch JF. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol. 1989;14:556-563.
61. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001;86:5396-5404.
62. Clarkson TB. Progression and regression of nonhuman primate coronary artery atherosclerosis: considerations of experimental design. In: Malinow MR, Blaton VH, eds. Regression of Atherosclerotic Lesions. New York: Plenum; 1984:43-60.
63. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:217-221.
64. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002;346:967-974.
65. Herrington DM, Howard TD, Brosnihan DB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002;105:1879-1882.
66. Viscoli CM, Brass LM, Keman WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
67. Herrington DM, Reboussin DM, Broshihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-529.
68. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju PI, Harper KD, for the MORE Investigators. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;847:847-857.
69. Hodis HN, Mack WJ, Lobo PA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu C, Liu C, Azen SP, for the Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 12001;35:939-953.
70. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817-824.